{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T16:30:17Z","timestamp":1762101017122,"version":"build-2065373602"},"reference-count":24,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2010,3,25]],"date-time":"2010-03-25T00:00:00Z","timestamp":1269475200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2010,9]]},"abstract":"<jats:p>\n                    <jats:bold>Aim:<\/jats:bold>\n                    Ablation of gastric inhibitory polypeptide (GIP) receptor signalling can prevent many of the metabolic abnormalities associated with dietary\u2010induced obesity\u2010diabetes. The present study was designed to assess the ability of active immunization against (Pro\n                    <jats:sup>3<\/jats:sup>\n                    )GIP to counter metabolic dysfunction associated with diet\u2010induced obesity in high\u2010fat\u2010fed mice.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    Normal male Swiss NIH mice were injected (s.c.) once every 14 days for 98 days with complexed (Pro\n                    <jats:sup>3<\/jats:sup>\n                    )GIP peptide, with transfer to a high\u2010fat diet on day 21.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    Active immunization against (Pro\n                    <jats:sup>3<\/jats:sup>\n                    )GIP resulted in circulating GIP antibody production and significantly (p &lt; 0.05 p &lt; 0.01) reduced circulating blood glucose concentrations compared to high\u2010fat control mice from day 84 onwards. Glucose levels were not significantly different from lean controls. The glycaemic response to i.p. glucose was correspondingly improved (p &lt; 0.01) in (Pro\n                    <jats:sup>3<\/jats:sup>\n                    )GIP\u2010immunized mice. Furthermore, circulating and glucose\u2010stimulated plasma insulin levels were significantly (p &lt; 0.01 to p &lt; 0.001) depressed compared to high\u2010fat control mice. Liver triglyceride, pancreatic insulin and circulating LDL\u2010cholesterol levels were also significantly reduced in (Pro\n                    <jats:sup>3<\/jats:sup>\n                    )GIP\u2010immunized mice. These changes were independent of any effects on food intake or body weight. The glucose\u2010lowering effect of native GIP was annulled in (Pro\n                    <jats:sup>3<\/jats:sup>\n                    )GIP\u2010immunized mice consistent with the induction of biologically effective GIP\u2010specific neutralizing antibodies.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    These results suggest that immunoneutralization of GIP represents an effective means of countering the disruption of metabolic processes induced by high\u2010fat feeding.\n                  <\/jats:p>","DOI":"10.1111\/j.1463-1326.2010.01228.x","type":"journal-article","created":{"date-parts":[[2010,3,25]],"date-time":"2010-03-25T15:10:38Z","timestamp":1269529838000},"page":"744-751","source":"Crossref","is-referenced-by-count":25,"title":["Active immunization against (Pro\n                    <sup>3<\/sup>\n                    )GIP improves metabolic status in high\u2010fat\u2010fed mice"],"prefix":"10.1111","volume":"12","author":[{"given":"I. A.","family":"Montgomery","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Irwin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. R.","family":"Flatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,7,23]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.333.7572.794"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/82.1.248S"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-009-1422-8"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1515\/BC.2009.002"},{"key":"e_1_2_6_6_2","first-page":"61","article-title":"GIP\u2010based therapeutics for diabetes and obesity","volume":"2","author":"Irwin N","year":"2007","journal-title":"Curr Chem Biol"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1210\/endo.139.9.6288"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.2337\/diab.27.3.327"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.2337\/diab.32.5.433"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1677\/joe.0.1010249"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1530\/acta.0.1120224"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm727"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2005.07.164"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00460.2007"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI25483"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.2002.6364"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.54.8.2436"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-007-0710-4"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-007-0692-2"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M710466200"},{"key":"e_1_2_6_21_2","first-page":"S373","article-title":"Novel low\u2010molecular weight antagonist of glucose\u2010dependent insulinotropic polypeptide receptor, SKL14959, prevents obesity and insulin resistance","volume":"51","author":"Tsubamoto Y","year":"2008","journal-title":"Diabetologia"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00252768"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.npep.2003.09.002"},{"key":"e_1_2_6_24_2","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0016-5085(79)80219-X","article-title":"Release of gastric inhibitory polypeptide (GIP) by intraduodenal acidification in rats and humans and abolishment of the incretin effect of acid by GIP\u2010antiserum in rats","volume":"76","author":"Ebert R","year":"1979","journal-title":"Gastroenterology"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M609088200"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1463-1326.2010.01228.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/j.1463-1326.2010.01228.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T05:14:20Z","timestamp":1761887660000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/j.1463-1326.2010.01228.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,23]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["10.1111\/j.1463-1326.2010.01228.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1463-1326.2010.01228.x","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"type":"print","value":"1462-8902"},{"type":"electronic","value":"1463-1326"}],"subject":[],"published":{"date-parts":[[2010,7,23]]}}}